DISCLAIMER:

This product is strictly intended for research purposes only. It is not for human consumption. Do not ingest, inject, or otherwise administer this product. All images and labels on this website must contain the warning “NOT FOR HUMAN CONSUMPTION.”

This high-potency blend contains two of the most extensively studied regenerative peptides in the research community: BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4 Acetate). When combined, these peptides are often used in experimental settings for synergistic investigations into wound healing, tissue regeneration, inflammation modulation, and musculoskeletal recovery.

How Does the BPC-157 + TB-500 Blend Work?

BPC-157 is a peptide fragment derived from a naturally occurring protein in the human gastric system. It has been shown in studies to accelerate the healing of soft tissue, tendons, ligaments, and even bone. It also exhibits anti-inflammatory properties and protective effects on organs.

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide that plays a crucial role in cellular migration, angiogenesis (formation of new blood vessels), and the repair of damaged tissues. It promotes healing by regulating actin, a protein involved in cell movement and structure.

Together, BPC-157 and TB-500 may provide an amplified healing response in research models, making this combination a powerful tool in studies related to injury recovery and systemic inflammation.

Theoretical Benefits of BPC-157 + TB-500 Blend (for research use only):

• Accelerated Healing of Injuries:

The blend may significantly reduce recovery time in tendon, ligament, and muscle injuries, based on preclinical trials.

• Anti-Inflammatory Effects:

Both peptides have been shown to modulate pro-inflammatory cytokines, reducing systemic inflammation in models of autoimmune and chronic inflammatory diseases.

• Angiogenesis & Blood Flow:

TB-500 promotes angiogenesis and improves blood flow to injured areas, potentially enhancing the effects of BPC-157 in localized healing.

• Gastrointestinal Protection (BPC-157):

BPC-157 has demonstrated protective effects on the gut lining, reducing lesions and improving recovery in models of inflammatory bowel disease.

• Neuroprotective Potential:

Early-stage research suggests these peptides may assist in the repair of nerve tissue, aiding in the study of neuropathic conditions and neuroregeneration.

• Joint & Connective Tissue Support:

This combination is of particular interest in studies on arthritis, joint degeneration, and chronic tendonitis.

Usage in Research:

This product is typically reconstituted with bacteriostatic water and administered subcutaneously near the site of study. Due to the high concentration, most researchers opt for microdosing protocols. For example, adding 2mL of bacteriostatic water yields 0.1mL = 1mg of each peptide. Daily injections of 0.1–0.2mL are common in ongoing recovery-based studies lasting 2–4 weeks.

Pharmacokinetics:

• BPC-157 Half-life: Variable (short plasma half-life but prolonged biological effect)

• TB-500 Half-life: ~2–3 days

• Bioavailability (s.c.): High for both

• Metabolism: Proteolytic degradation

Safety and Adverse Effects (observed in research):

• BPC-157 is reported to be well tolerated in rodent models, with no significant toxicology flagged in chronic use studies.

• TB-500 may cause temporary fatigue or dizziness post-administration in some studies.

• Neither compound has shown carcinogenic effects in animal models.

• Due to the angiogenic nature of TB-500, caution is advised when researching in models with tumor susceptibility.

Comparisons with Other Peptides:

This blend is often compared to individual administration of BPC-157 or TB-500, but anecdotal and early-stage data suggest that combining the two may enhance regenerative potential through complementary mechanisms — BPC focusing on cellular protection and TB-500 on cellular migration and vascularization.

Research Highlights:

• In a study by Sikiric et al., BPC-157 accelerated the healing of transected tendons and ligaments in rodent models.

• TB-500 has been shown to improve cardiac function post-myocardial infarction and support skeletal muscle regeneration after trauma.

Legal and Compliance Notes:

BPC-157 and TB-500 are not approved for human or veterinary use outside of clinical trials. These substances are offered exclusively for laboratory research and experimental analysis. Any application involving human use is strictly prohibited and unlawful under current regulatory frameworks.